Source: ALL

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1788
Gene Symbol: DNMT3A
DNMT3A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.300 ModifyingMutation RGD The average number of methylated genes during carcinogenesis was significantly correlated with DNMT1 and DNMT3a protein expression levels. 21163286

2011

Entrez Id: 1786
Gene Symbol: DNMT1
DNMT1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.300 ModifyingMutation RGD The average number of methylated genes during carcinogenesis was significantly correlated with DNMT1 and DNMT3a protein expression levels. 21163286

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in KRAS-mutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types. 26595770

2016

Entrez Id: 406986
Gene Symbol: MIR203A
MIR203A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Therapeutic CTD_human Moreover, we identified that miR-203 may suppress the tumorigenesis at least in part through negatively regulating its target gene ABL1. 23968727

2013

Entrez Id: 4780
Gene Symbol: NFE2L2
NFE2L2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human The carcinogenesis of prostate cancer (PCa) in TRAMP model is highly correlated with hypermethylation in the promoter region of Nrf2 and the accompanying reduced transcription of Nrf2 and its regulated detoxifying genes. 29228771

2018

Entrez Id: 25
Gene Symbol: ABL1
ABL1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human Moreover, we identified that miR-203 may suppress the tumorigenesis at least in part through negatively regulating its target gene ABL1. 23968727

2013

Entrez Id: 406935
Gene Symbol: MIR143
MIR143
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Therapeutic CTD_human In addition, we found that adenovirus over-expression of pre-miR-143 reduced tumorigenesis in vivo. 28736328

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. 29247004

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. 25221644

2014

Entrez Id: 857
Gene Symbol: CAV1
CAV1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. 29247004

2018

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF(V600E)-driven signalling and tumorigenesis in mice and human cell settings. 24717435

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker CTD_human Furthermore, while inactivation of Arf appears to be crucial for MM pathogenesis, the inactivation of both p16(Ink4a) and p19(Arf) cooperate to accelerate asbestos-induced tumorigenesis. 21526190

2011

Entrez Id: 1523
Gene Symbol: CUX1
CUX1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.370 Biomarker CTD_human Thus, our complementary approaches identify CUX1 as a pan-driver of tumorigenesis and uncover a potential strategy for treating CUX1-mutant tumors. 24316979

2014

Entrez Id: 5048
Gene Symbol: PAFAH1B1
PAFAH1B1
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.330 Biomarker CTD_human Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. 24487275

2014

Entrez Id: 692088
Gene Symbol: SNORD50B
SNORD50B
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.300 Biomarker CTD_human In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in KRAS-mutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types. 26595770

2016

Entrez Id: 26799
Gene Symbol: SNORD50A
SNORD50A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.300 Biomarker CTD_human In agreement with this hypothesis, CRISPR-mediated deletion of SNORD50A and SNORD50B in KRAS-mutant tumor cells enhanced tumorigenesis, and SNORD50A and SNORD50B deletion and oncogenic KRAS mutation co-occurred significantly in multiple human tumor types. 26595770

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE Notably, although ErbB2 does not bind any ErbB ligands, ErbB2 may activate tumorigenesis via a heterodimer, rather than a homodimer. 26935861

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE A series of studies has revealed that mutations of KRAS are involved in gastric carcinogenesis. 19639197

2009

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Considering the above results of PCR-SSCP and RT-PCR, genetic alterations of the p16 gene are rarely implicated in human gastric cancer tumorigenesis. 9222307

1997

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results provide new insights into mutant KRAS function and its role in carcinogenesis. 23580570

2013

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 AlteredExpression BEFREE In melanoma, constitutive activation of the BRAF/MEK/ERK (MAPK) and PI3K/AKT/mTOR (PI3K) signaling pathways plays a pivotal role in cell proliferation, survival and tumorigenesis. 26299806

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results suggest that (1) the K-ras and p53 gene alterations would have no special roles in terms of the lung carcinogenesis in young adults; (2) a positive relationship between smoking and p53 gene alteration would exist in young adults with lung cancer, and (3) K-ras gene alteration would become a prognostic factor in lung cancer. 7715905

1995

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors. 29435002

2018

Entrez Id: 4780
Gene Symbol: NFE2L2
NFE2L2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Highlighting the importance of this pathway as a determinant of susceptibility to carcinogenesis, multiple studies now demonstrate enhanced incidence, multiplicity, and/or tumor burden in Nrf2-disrupted mice compared to wild-type in models of inflammation and colon cancer, bladder cancer, lung disease and cancer, stomach cancer, mammary cancer, skin cancer, and hepatocarcinogenesis. 21369766

2011

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 Biomarker BEFREE CPNE3, a member of a Ca<sup>2+</sup> -dependent phospholipid-binding protein family, was identified as a ligand of ERBB2 and has a more general role in carcinogenesis. 28670859

2017